{
    "clinical_study": {
        "@rank": "63797", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intramuscular (IM), single dose"
            }, 
            {
                "arm_group_label": "ETI-204", 
                "arm_group_type": "Experimental", 
                "description": "Intramuscular (IM), single dose"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to evaluate the safety and local tolerability of single intramuscular (IM)\n      doses of ETI-204; to evaluate the pharmacokinetics (PK) of a single IM dose of ETI-204; and\n      to evaluate the immunogenicity of a single IM dose of ETI-204."
        }, 
        "brief_title": "Safety, Tolerability, and PK of Single IM Doses of ETI-204 in Adult Volunteers", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Inhalational Anthrax", 
        "condition_browse": {
            "mesh_term": "Anthrax"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Females or males \u226518 years of age;\n\n          2. All females regardless of childbearing potential must have a negative serum beta\n             human chorionic gonadotropin (\u03b2-hCG) pregnancy test at Screening and Day -1;\n\n          3. Females of childbearing potential (i.e., not postmenopausal or surgically sterile)\n             must agree to practice abstinence or to use a medically accepted method of\n             contraception from the time of Screening through 30 days after the final study visit.\n             Acceptable methods of contraception include diaphragm/cervical cap with spermicide;\n             sponge with spermicide; condom with spermicide; or intrauterine device with condom or\n             spermicide. The following contraceptive methods are acceptable only when used with a\n             condom and spermicide: birth control pills, birth control patches, vaginal ring,\n             hormone under the skin, or hormone injections;\n\n          4. Postmenopausal females, defined as females who have had amenorrhea for at least 12\n             months either naturally or following cessation of all exogenous hormonal treatments,\n             and have a follicle stimulating hormone level of >40 mIU/mL at Screening;\n\n          5. Females who have undergone surgical sterilization, including hysterectomy, bilateral\n             oophorectomy, bilateral salpingectomy, tubal ligation, or tubal essure;\n\n          6. Males must agree to practice abstinence or use a condom with spermicide and to\n             refrain from sperm donation from Screening during the study and for 30 days after the\n             final study visit;\n\n          7. Provide written informed consent;\n\n          8. Willing to comply with study restrictions.\n\n        Exclusion Criteria:\n\n          1. Body weight >100 kg;\n\n          2. Body mass index \u226532 kg/m2;\n\n          3. Pregnant or lactating female;\n\n          4. Clinically significant comorbidity that would interfere with completion of the study\n             procedures or objectives, or compromise the subject's safety;\n\n          5. Supine systolic blood pressure (BP) \u2265150 mmHg or \u226490 mmHg or diastolic BP \u226595 mmHg;\n\n          6. Use of H1 receptor antagonists (i.e., antihistamines) within 5 days prior to Day 1;\n\n          7. Evidence of drug or alcohol abuse within 6 months of Day 1 as determined by the\n             Investigator;\n\n          8. Positive test result for drugs of abuse (with the exception of medically prescribed\n             drugs) at Screening or on Day -1;\n\n          9. Positive test for alcohol at Screening, subject to Investigator's discretion.\n             Subjects who test positive for alcohol at Day -1 are excluded from the study;\n\n         10. Treatment with an investigational agent within 30 days or 5 half-lives of the\n             investigational agent at Day 1 (whichever is longer);\n\n         11. Congenital or acquired immunodeficiency syndrome;\n\n         12. Prior solid organ or bone marrow transplant;\n\n         13. Positive test for Hepatitis B (surface antigen), Hepatitis C, or human\n             immunodeficiency virus (HIV) at Screening;\n\n         14. History of prior treatment for anthrax exposure or prior anthrax infection;\n\n         15. Prior immunization with any approved or investigational anthrax vaccine or prior\n             treatment with an investigational anthrax treatment (e.g., ETI-204, raxibacumab, or\n             anthrax immune globulin);\n\n         16. Military personnel deployed in 1990 or after, unless the subject can provide\n             documentation demonstrating he or she has not previously received any approved or\n             investigational anthrax vaccine;\n\n         17. Use of systemic steroids, immunosuppressive agents, anticoagulants, or\n             anti-arrhythmics within 1 year prior to Day 1. A single short course (i.e., less than\n             14 days) of systemic steroid therapy is allowed, provided it concluded more than 6\n             months prior to Day 1;\n\n         18. Donation or loss of >500 mL of blood within 30 days or plasma within 7 days of Day 1;\n\n         19. Prior stroke, epilepsy, relapsing or degenerative central nervous system disease, or\n             relapsing or degenerative ocular disease;\n\n         20. Myocardial infarction or acute coronary syndrome in the past 5 years, active angina\n             pectoris, or heart failure (New York Heart Association scale >1);\n\n         21. History of chronic liver disease;\n\n         22. Calculated creatinine clearance of <30 mL/min using the Cockcroft-Gault equation;\n\n         23. Any clinically significant abnormality, in the Investigator's opinion, on\n             electrocardiogram (ECG) or clinical laboratory tests (hematology, clinical chemistry,\n             or urinalysis) at Screening. Out of range tests may be repeated to confirm;\n\n         24. History of allergic or hypersensitivity reaction or hives to other therapeutic\n             antibodies or immunoglobulins;\n\n         25. History of any malignant neoplasm within the last 5 years, with the exception of\n             adequately treated localized or in situ non-melanoma carcinoma of the skin (e.g.,\n             basal cell carcinoma) or the cervix;\n\n         26. Subjects who, in the opinion of the Investigator, are not suitable candidates for\n             enrollment or who may not comply with the requirements of the study.\n\n         27. Platelet count <140 K/\u00b5L;\n\n         28. Prothrombin time/international normalized ratio or activated partial thromboplastin\n             time >1.2 X the upper limit of normal at Screening or Day -1;\n\n         29. Poor muscle mass as determined by the Investigator;\n\n         30. Family or personal history of a bleeding disorder;\n\n         31. History of unexplained bleeding;\n\n         32. Use of any anticoagulant or anti-platelet drug for 3 months prior to Screening. At\n             the discretion of the Investigator, daily aspirin may be taken for general health\n             reasons."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932437", 
            "org_study_id": "AH106"
        }, 
        "intervention": [
            {
                "arm_group_label": "ETI-204", 
                "description": "monoclonal antibody", 
                "intervention_name": "ETI-204", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo comparator", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological", 
                "other_name": "Placebo comparator"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "contact": {
                "email": "alex.king@covance.com", 
                "last_name": "Alex King, MD", 
                "phone": "214-647-9399"
            }, 
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75247"
                }, 
                "name": "Covance Clinical Research Unit Inc."
            }, 
            "investigator": {
                "last_name": "Alex King, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intramuscular Doses of ETI-204 in Adult Volunteers", 
        "overall_contact": {
            "email": "alex.king@covance.com", 
            "last_name": "Alex King, MD", 
            "phone": "214-647-9399"
        }, 
        "overall_contact_backup": {
            "email": "debra.mandarino@covance.com", 
            "last_name": "Debra Mandarino, MD", 
            "phone": "608-443-1502"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety assessments will be assessed by collecting and monitoring vital signs, clinical laboratory tests, ECGs, physical examinations, injection site assessments, skin assessments for presence/absence of rash,  and AEs.", 
            "measure": "Number of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "71 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932437"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "All PK parameters will be descriptively analyzed and reported by treatment group for the PK analysis population.", 
                "measure": "Pharmacokinetics (PK) profiles", 
                "safety_issue": "No", 
                "time_frame": "71 days"
            }, 
            {
                "description": "Anti-ETI-204 antibody concentrations at each timepoint will be listed by subject.", 
                "measure": "To evaluate the immunogenicity of a single IM dose of ETI-204", 
                "safety_issue": "No", 
                "time_frame": "71 days"
            }
        ], 
        "source": "Elusys Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Elusys Therapeutics", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}